Identification

Name
Toloxatone
Accession Number
DB09245
Type
Small Molecule
Groups
Approved
Description

Toloxatone is an antidepressant launched in 1984 in France for the treatment of depression. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [5].

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Humoryl (Sanofi Aventis)
Categories
UNII
5T206015T5
CAS number
29218-27-7
Weight
Average: 207.229
Monoisotopic: 207.089543283
Chemical Formula
C11H13NO3
InChI Key
MXUNKHLAEDCYJL-UHFFFAOYSA-N
InChI
InChI=1S/C11H13NO3/c1-8-3-2-4-9(5-8)12-6-10(7-13)15-11(12)14/h2-5,10,13H,6-7H2,1H3
IUPAC Name
5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one
SMILES
CC1=CC(=CC=C1)N1CC(CO)OC1=O

Pharmacology

Indication

For the treatment of major depressive disorder.

Pharmacodynamics

This drug has been shown to help manage the symptoms of depression by maintaining neuro-synaptic levels of serotonin and catecholamines while regulating their metabolism, which leads to relief of depressive symptoms [1].

Mechanism of action

This medication is a reversible inhibitor of monoamine oxidase type-A (also known as RIMA).
MAO-A can be found in norepinephrinergic and serotonergic neurons and regulates the metabolism of serotonin and catecholamines, allowing for increased circulation in the synaptic cleft. Traditional monoamine oxidase inhibitors irreversibly inhibit monoamine oxidase and therefore, side effects, drug interactions, and food interactions persist as long as 2-3 weeks after discontinuing toloxatone. The elevation of serotonin and norepinephrine levels occurs rapidly after medication administration. However, the therapeutic relief of depressive symptoms requires weeks of daily treatment to observe results. Selective and reversible MAO-A inhibitors are more effective in treating major depression without several of the drug and food interactions associated with traditional monoamine oxidase inhibitors [6].

TargetActionsOrganism
UAmine oxidase [flavin-containing] A
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Mainly hepatic 1% of drug is excreted unchanged in the urine [3]

Half life

1-3 h [3]

Clearance

High hepatic excretion rate [3]

Toxicity

In rare cases, toloxatone toxicity may cause fulminant hepatitis [6]. More common adverse effects include dysuria, nausea, constipation, vertigo, and insomnia. Administration of toloxatone can lead to an increased risk of serotonin syndrome with selective serotonin reuptake inhibitors (SSRI), and tricyclic antidepressants [6]. Increased blood pressure can occur with sympathomimetic medication coadministration. One study showed that when combined with meals, elevated doses of toloxatone may contribute to elevated blood pressure in healthy subjects. This pharmacodynamic interaction could be explained by enhanced tyramine bioavailability in the presence of toloxatone. This tyramine in meals and toloxatone is unlikely to occur in patients after long-term administration of the drug at therapeutic dosages [2].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineToloxatone may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Toloxatone.Experimental
3,4-MethylenedioxyamphetamineToloxatone may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineToloxatone may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineToloxatone may increase the hypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Toloxatone.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineToloxatone may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbediterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Abediterol.Investigational
AcarboseToloxatone may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololToloxatone may increase the hypotensive activities of Acebutolol.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Toloxatone.Experimental
AlbiglutideToloxatone may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilToloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Alfentanil.Approved, Illicit
AliskirenToloxatone may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Toloxatone.Approved, Investigational
AlogliptinToloxatone may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Toloxatone.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Toloxatone.Illicit
AlprenololToloxatone may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Toloxatone.Approved
AmbrisentanToloxatone may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptineToloxatone may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylineToloxatone may increase the serotonergic activities of Amitriptyline.Approved
AmitriptylinoxideToloxatone may increase the serotonergic activities of Amitriptylinoxide.Approved, Investigational
AmlodipineToloxatone may increase the hypotensive activities of Amlodipine.Approved
AmoxapineToloxatone may increase the serotonergic activities of Amoxapine.Approved
AmphetamineToloxatone may increase the hypertensive activities of Amphetamine.Approved, Illicit, Investigational
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Toloxatone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Arformoterol.Approved, Investigational
AtenololToloxatone may increase the hypotensive activities of Atenolol.Approved
AtomoxetineToloxatone may increase the central neurotoxic activities of Atomoxetine.Approved
AtropineToloxatone may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Bambuterol.Approved, Investigational
BenazeprilToloxatone may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideToloxatone may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinToloxatone may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetamineToloxatone may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilToloxatone may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Toloxatone.Approved, Investigational
BetaxololToloxatone may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineToloxatone may increase the hypotensive activities of Bethanidine.Approved
BezafibrateThe risk or severity of adverse effects can be increased when Toloxatone is combined with Bezafibrate.Approved, Investigational
BietaserpineToloxatone may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostToloxatone may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololToloxatone may increase the hypotensive activities of Bisoprolol.Approved
BitolterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Bitolterol.Withdrawn
BosentanToloxatone may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Toloxatone may increase the hypotensive activities of BQ-123.Investigational
BretyliumToloxatone may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe metabolism of Brexpiprazole can be decreased when combined with Toloxatone.Approved, Investigational
BrimonidineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Brimonidine.Approved
BrofaromineToloxatone may increase the hypertensive activities of Brofaromine.Experimental
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Toloxatone.Approved, Investigational
BupranololToloxatone may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Toloxatone.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Toloxatone is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Toloxatone is combined with Buspirone.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Toloxatone.Approved, Illicit, Vet Approved
ButriptylineToloxatone may increase the serotonergic activities of Butriptyline.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Toloxatone.Approved
CadralazineToloxatone may increase the hypotensive activities of Cadralazine.Experimental
CafedrineToloxatone may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinToloxatone may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanToloxatone may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilToloxatone may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilToloxatone may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilToloxatone may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Toloxatone.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Toloxatone.Illicit, Investigational, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Toloxatone.Approved, Investigational
CaroxazoneToloxatone may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololToloxatone may increase the hypotensive activities of Carteolol.Approved
CarvedilolToloxatone may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololToloxatone may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazideToloxatone may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineToloxatone may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamideToloxatone may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneToloxatone may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineToloxatone may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilToloxatone may increase the hypotensive activities of Cilazapril.Approved
CinitaprideThe metabolism of Cinitapride can be decreased when combined with Toloxatone.Approved, Investigational
CirazolineToloxatone may increase the hypertensive activities of Cirazoline.Experimental
CitalopramToloxatone may increase the serotonergic activities of Citalopram.Approved
ClemastineToloxatone may increase the anticholinergic activities of Clemastine.Approved, Investigational
ClenbuterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineToloxatone may increase the serotonergic activities of Clomipramine.Approved, Investigational, Vet Approved
ClonidineToloxatone may increase the hypertensive activities of Clonidine.Approved
CloranololToloxatone may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Toloxatone.Approved, Illicit
CryptenamineToloxatone may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Toloxatone.Approved
CyclopenthiazideToloxatone may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideToloxatone may increase the hypotensive activities of Cyclothiazide.Approved
CyproheptadineToloxatone may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinToloxatone may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Toloxatone.Investigational
DebrisoquinToloxatone may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilToloxatone may increase the hypotensive activities of Delapril.Experimental
DeserpidineToloxatone may increase the hypotensive activities of Deserpidine.Approved
DesipramineToloxatone may increase the serotonergic activities of Desipramine.Approved, Investigational
DesvenlafaxineToloxatone may increase the serotonergic activities of Desvenlafaxine.Approved, Investigational
DeutetrabenazineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Deutetrabenazine.Approved, Investigational
DexmethylphenidateToloxatone may increase the hypertensive activities of Dexmethylphenidate.Approved, Investigational
DextroamphetamineToloxatone may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanToloxatone may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Toloxatone.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Toloxatone.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Toloxatone.Approved, Investigational
DiazoxideToloxatone may increase the hypotensive activities of Diazoxide.Approved
DibenzepinToloxatone may increase the serotonergic activities of Dibenzepin.Experimental
DiethylnorspermineToloxatone may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylpropionToloxatone may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DihydralazineToloxatone may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Toloxatone.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Toloxatone.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Toloxatone.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Toloxatone.Experimental, Illicit
DiltiazemToloxatone may increase the hypotensive activities of Diltiazem.Approved, Investigational
DimetacrineToloxatone may increase the serotonergic activities of Dimetacrine.Approved, Withdrawn
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Toloxatone.Approved, Illicit
DipivefrinToloxatone may increase the hypertensive activities of Dipivefrin.Approved
DisopyramideToloxatone may increase the hypoglycemic activities of Disopyramide.Approved
DisulfiramThe risk or severity of convulsion can be increased when Toloxatone is combined with Disulfiram.Approved
DobutamineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Dobutamine.Approved
DomperidoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamideToloxatone may increase the hypotensive activities of Dorzolamide.Approved
DosulepinToloxatone may increase the serotonergic activities of Dosulepin.Approved
DoxapramToloxatone may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinToloxatone may increase the hypotensive activities of Doxazosin.Approved
DoxepinToloxatone may increase the serotonergic activities of Doxepin.Approved, Investigational
DoxofyllineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Doxofylline.Approved, Investigational
DoxylamineToloxatone may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Toloxatone.Experimental
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Toloxatone.Experimental, Illicit
DroxidopaToloxatone may increase the hypertensive activities of Droxidopa.Approved, Investigational
DulaglutideToloxatone may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineToloxatone may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Toloxatone.Experimental, Illicit
EfonidipineToloxatone may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Toloxatone.Approved, Investigational
EmpagliflozinToloxatone may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilToloxatone may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatToloxatone may increase the hypotensive activities of Enalaprilat.Approved
EndralazineToloxatone may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Toloxatone.Approved, Investigational
EpanololToloxatone may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Toloxatone is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineToloxatone may increase the hypertensive activities of Epinephrine.Approved, Vet Approved
EpoprostenolToloxatone may increase the hypotensive activities of Epoprostenol.Approved
EprosartanToloxatone may increase the hypotensive activities of Eprosartan.Approved
ErgonovineToloxatone may increase the hypertensive activities of Ergonovine.Approved
ErgotamineToloxatone may increase the hypertensive activities of Ergotamine.Approved
EscitalopramToloxatone may increase the serotonergic activities of Escitalopram.Approved, Investigational
EtafedrineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Etafedrine.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Toloxatone.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Toloxatone.Approved, Illicit
EtoperidoneToloxatone may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Toloxatone.Illicit, Vet Approved
ExenatideToloxatone may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipineToloxatone may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineToloxatone may increase the serotonergic activities of Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoldopamToloxatone may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Fenoterol.Approved, Investigational
FentanylToloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferulic acidToloxatone may increase the hypotensive activities of Ferulic acid.Experimental
FlibanserinThe metabolism of Flibanserin can be decreased when combined with Toloxatone.Approved, Investigational
FluoxetineToloxatone may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxamineToloxatone may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Formoterol.Approved, Investigational
FosinoprilToloxatone may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Toloxatone.Approved, Investigational
FurazolidoneToloxatone may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Toloxatone.Experimental
GliclazideToloxatone may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideToloxatone may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideToloxatone may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideToloxatone may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzToloxatone may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelToloxatone may increase the hypotensive activities of Guanadrel.Approved
GuanazodineToloxatone may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineToloxatone may increase the hypotensive activities of Guanethidine.Approved
GuanfacineToloxatone may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorToloxatone may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzToloxatone may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanToloxatone may increase the hypotensive activities of Guanoxan.Experimental
HarmalineToloxatone may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Toloxatone.Approved, Illicit, Investigational
HexamethoniumToloxatone may increase the hypotensive activities of Hexamethonium.Experimental
HexoprenalineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Hexoprenaline.Approved, Withdrawn
HydracarbazineToloxatone may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazineToloxatone may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideToloxatone may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Toloxatone.Approved, Illicit
HydroflumethiazideToloxatone may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Toloxatone.Approved, Illicit
HydroxyamphetamineToloxatone may increase the hypertensive activities of Hydroxyamphetamine.Approved
ImidaprilToloxatone may increase the hypotensive activities of Imidapril.Investigational
ImipramineToloxatone may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Indacaterol.Approved
IndalpineToloxatone may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideToloxatone may increase the hypotensive activities of Indapamide.Approved
IndenololToloxatone may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminToloxatone may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartToloxatone may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirToloxatone may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineToloxatone may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineToloxatone may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanToloxatone may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproToloxatone may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Toloxatone.Approved
IprindoleToloxatone may increase the serotonergic activities of Iprindole.Experimental
IproclozideToloxatone may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Toloxatone.Withdrawn
IrbesartanToloxatone may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidThe therapeutic efficacy of Toloxatone can be increased when used in combination with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Isoprenaline.Approved, Investigational
IsradipineToloxatone may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinToloxatone may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Toloxatone.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Toloxatone.Approved, Nutraceutical, Withdrawn
LabetalolToloxatone may increase the hypotensive activities of Labetalol.Approved
LacidipineToloxatone may increase the hypotensive activities of Lacidipine.Approved, Investigational
LatanoprostToloxatone may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineToloxatone may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Toloxatone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Toloxatone.Approved, Investigational
LevomilnacipranToloxatone may increase the serotonergic activities of Levomilnacipran.Approved, Investigational
LevonordefrinToloxatone may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Toloxatone.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Levosalbutamol.Approved, Investigational
LinezolidThe risk or severity of adverse effects can be increased when Toloxatone is combined with Linezolid.Approved, Investigational
LinsidomineToloxatone may increase the hypotensive activities of Linsidomine.Experimental
LiraglutideToloxatone may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetamineToloxatone may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilToloxatone may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Toloxatone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Toloxatone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Toloxatone.Illicit
LofepramineToloxatone may increase the serotonergic activities of Lofepramine.Experimental
LofexidineThe metabolism of Lofexidine can be decreased when combined with Toloxatone.Approved, Investigational
LorpiprazoleThe risk or severity of serotonin syndrome can be increased when Lorpiprazole is combined with Toloxatone.Approved
LosartanToloxatone may increase the hypotensive activities of Losartan.Approved
MacitentanToloxatone may increase the hypotensive activities of Macitentan.Approved
ManidipineToloxatone may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Maprotiline.Approved, Investigational
MebanazineToloxatone may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylamineToloxatone may increase the hypotensive activities of Mecamylamine.Approved, Investigational
MecaserminToloxatone may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MelitracenToloxatone may increase the serotonergic activities of Melitracen.Experimental, Investigational
MephedroneToloxatone may increase the hypertensive activities of Mephedrone.Investigational
MephentermineToloxatone may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Toloxatone.Experimental
MequitazineToloxatone may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolToloxatone may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminToloxatone may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Toloxatone.Approved, Illicit
MethamphetamineToloxatone may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidineToloxatone may increase the hypotensive activities of Methoserpidine.Experimental
MethoxamineToloxatone may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Toloxatone.Experimental
MethyldopaThe risk or severity of hypertension can be increased when Toloxatone is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Toloxatone.Experimental
Methylene blueToloxatone may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateToloxatone may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MethysergideThe metabolism of Methysergide can be decreased when combined with Toloxatone.Approved
MetipranololToloxatone may increase the hypotensive activities of Metipranolol.Approved
MetolazoneToloxatone may increase the hypotensive activities of Metolazone.Approved
MetoprololToloxatone may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineToloxatone may increase the hypotensive activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Toloxatone is combined with Mianserin.Approved, Investigational
MibefradilToloxatone may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineToloxatone may increase the hypertensive activities of Midodrine.Approved
MidomafetamineToloxatone may increase the hypertensive activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneToloxatone may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolToloxatone may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranToloxatone may increase the serotonergic activities of Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the hypertensive activities of Toloxatone.Approved
MinoxidilToloxatone may increase the hypotensive activities of Minoxidil.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Mirtazapine.Approved
MMDAToloxatone may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Toloxatone is combined with Moclobemide.Approved, Investigational
MoexiprilToloxatone may increase the hypotensive activities of Moexipril.Approved
MorphineThe therapeutic efficacy of Morphine can be increased when used in combination with Toloxatone.Approved, Investigational
MoxonidineToloxatone may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineToloxatone may increase the hypotensive activities of Muzolimine.Experimental
NadololToloxatone may increase the hypotensive activities of Nadolol.Approved
NaftopidilToloxatone may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Toloxatone.Approved
NaluzotanThe metabolism of Naluzotan can be decreased when combined with Toloxatone.Investigational
NaphazolineToloxatone may increase the hypertensive activities of Naphazoline.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Toloxatone.Approved, Investigational
NateglinideToloxatone may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololToloxatone may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneToloxatone may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Toloxatone.Withdrawn
NicardipineToloxatone may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilToloxatone may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineToloxatone may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineToloxatone may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineToloxatone may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineToloxatone may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineToloxatone may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussideToloxatone may increase the hypotensive activities of Nitroprusside.Approved, Investigational
NorepinephrineToloxatone may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Toloxatone.Approved, Illicit
NortriptylineToloxatone may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinToloxatone may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineToloxatone may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlmesartanToloxatone may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Olodaterol.Approved
OmapatrilatToloxatone may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolToloxatone may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Toloxatone.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Orciprenaline.Approved
OxprenololToloxatone may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Oxycodone.Approved, Illicit, Investigational
OxymetazolineToloxatone may increase the hypertensive activities of Oxymetazoline.Approved, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Toloxatone.Approved, Investigational, Vet Approved
PargylinePargyline may increase the hypertensive activities of Toloxatone.Approved
ParoxetineToloxatone may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololToloxatone may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidineToloxatone may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Toloxatone.Approved, Vet Approved
PentoliniumToloxatone may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Toloxatone.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilToloxatone may increase the hypotensive activities of Perindopril.Approved
PethidineToloxatone may increase the hypotensive and central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PF-00610355The risk or severity of adverse effects can be increased when Toloxatone is combined with PF-00610355.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Toloxatone.Experimental
PhendimetrazineToloxatone may increase the hypertensive activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypertensive activities of Toloxatone.Approved
PheniprazineToloxatone may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Toloxatone.Experimental
PhenoxybenzamineToloxatone may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazineToloxatone may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhentermineToloxatone may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolamineToloxatone may increase the hypotensive activities of Phentolamine.Approved
PhenylephrineToloxatone may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Toloxatone.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Toloxatone.Investigational
PinacidilToloxatone may increase the hypotensive activities of Pinacidil.Approved
PindololToloxatone may increase the hypotensive activities of Pindolol.Approved, Investigational
PioglitazoneToloxatone may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Toloxatone.Approved, Investigational
PirlindolePirlindole may increase the hypertensive activities of Toloxatone.Approved
PivhydrazineToloxatone may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenToloxatone may increase the anticholinergic activities of Pizotifen.Approved
Platelet Activating FactorToloxatone may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideToloxatone may increase the hypotensive activities of Polythiazide.Approved
PramlintideToloxatone may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinToloxatone may increase the hypotensive activities of Prazosin.Approved
ProcaineToloxatone may increase the hypertensive activities of Procaine.Approved, Investigational, Vet Approved
ProcarbazineToloxatone may increase the hypertensive activities of Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Procaterol.Approved, Investigational
PropranololToloxatone may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtokylolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Protokylol.Approved, Vet Approved
ProtriptylineToloxatone may increase the serotonergic activities of Protriptyline.Approved
PseudoephedrineToloxatone may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilToloxatone may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineToloxatone may increase the hypoglycemic activities of Quinine.Approved
RacepinephrineToloxatone may increase the hypertensive activities of Racepinephrine.Approved
RamiprilToloxatone may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Toloxatone.Approved
RemifentanilToloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Remifentanil.Approved
RemikirenToloxatone may increase the hypotensive activities of Remikiren.Approved
RepaglinideToloxatone may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineToloxatone may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Reserpine.Approved, Investigational
RilmenidineToloxatone may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RiociguatToloxatone may increase the hypotensive activities of Riociguat.Approved
RitobegronToloxatone may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Ritodrine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Toloxatone.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Toloxatone.Approved, Investigational
RosiglitazoneToloxatone may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Toloxatone.Approved
SafrazineToloxatone may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Salmeterol.Approved
SaprisartanToloxatone may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinToloxatone may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Toloxatone.Approved, Investigational, Vet Approved
SelexipagToloxatone may increase the hypotensive activities of Selexipag.Approved
SertralineToloxatone may increase the serotonergic activities of Sertraline.Approved
SitagliptinToloxatone may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanToloxatone may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilToloxatone may increase the hypotensive activities of Spirapril.Approved
SufentanilToloxatone may increase the central nervous system depressant (CNS depressant) and hypertensive activities of Sufentanil.Approved, Investigational
SulfadiazineToloxatone may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleToloxatone may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleToloxatone may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Toloxatone.Approved, Investigational
SunitinibToloxatone may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololToloxatone may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Toloxatone.Approved
TelmisartanToloxatone may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilToloxatone may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Terbutaline.Approved
TerlipressinToloxatone may increase the hypotensive activities of Terlipressin.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Toloxatone is combined with Tetrabenazine.Approved, Investigational
TetrahydrocannabivarinThe metabolism of Tetrahydrocannabivarin can be decreased when combined with Toloxatone.Investigational
TetrahydropalmatineToloxatone may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineToloxatone may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalineToloxatone may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Toloxatone.Approved, Investigational
TiboloneToloxatone may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenToloxatone may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Toloxatone.Experimental
TimololToloxatone may increase the hypotensive activities of Timolol.Approved
TolazamideToloxatone may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineToloxatone may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideToloxatone may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Toloxatone.Approved, Withdrawn
TolonidineToloxatone may increase the hypotensive activities of Tolonidine.Experimental
TorasemideToloxatone may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Toloxatone.Approved, Investigational
TrandolaprilToloxatone may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypertensive activities of Toloxatone.Approved, Investigational
TravoprostToloxatone may increase the hypotensive activities of Travoprost.Approved
TrazodoneToloxatone may increase the serotonergic activities of Trazodone.Approved, Investigational
TreprostinilToloxatone may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazideToloxatone may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinToloxatone may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanToloxatone may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipramineToloxatone may increase the serotonergic activities of Trimipramine.Approved
UnoprostoneToloxatone may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilToloxatone may increase the hypotensive activities of Urapidil.Investigational
ValsartanToloxatone may increase the hypotensive activities of Valsartan.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Toloxatone.Approved
VenlafaxineToloxatone may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Toloxatone is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Toloxatone.Approved
VincamineToloxatone may increase the hypotensive activities of Vincamine.Experimental
VinpocetineToloxatone may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Toloxatone.Approved, Investigational
XipamideToloxatone may increase the hypotensive activities of Xipamide.Experimental
XylometazolineToloxatone may increase the hypertensive activities of Xylometazoline.Approved, Investigational
ZimelidineToloxatone may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Toloxatone.Approved
ZofenoprilToloxatone may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Toloxatone.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805-16. [PubMed:1705137]
  2. Provost JC, Funck-Brentano C, Rovei V, D'Estanque J, Ego D, Jaillon P: Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther. 1992 Oct;52(4):384-93. [PubMed:1424410]
  3. Schoerlin MP, Guentert TW: [Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human]. Psychiatr Prax. 1989 Aug;16 Suppl 1:11-7. [PubMed:2685852]
  4. A reversible monoamine oxidase inhibitor, toloxatone: spectrophotometric and molecular orbital studies of the interaction with flavin adenine dinucleotide (FAD) [Link]
  5. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects [Link]
  6. Tolaxatone [Link]
  7. Chemistry [Link]
External Links
KEGG Drug
D02559
PubChem Compound
34521
PubChem Substance
310265148
ChemSpider
31769
BindingDB
50110725
ChEMBL
CHEMBL18116
Wikipedia
Toloxatone
ATC Codes
N06AG03 — Toloxatone

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)333[L1392]
water solubility1.22e-02 [L1392]
logP1.26[L1392]
Predicted Properties
PropertyValueSource
Water Solubility54.9 mg/mLALOGPS
logP0.61ALOGPS
logP1.41ChemAxon
logS-0.58ALOGPS
pKa (Strongest Acidic)14.61ChemAxon
pKa (Strongest Basic)-1.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity54.7 m3·mol-1ChemAxon
Polarizability21.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as toluenes. These are compounds containing a benzene ring which bears a methane group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Toluenes
Direct Parent
Toluenes
Alternative Parents
Oxazolidinones / Carbamate esters / Organic carbonic acids and derivatives / Oxacyclic compounds / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Toluene / Oxazolidinone / Oxazolidine / Carbamic acid ester / Carbonic acid derivative / Organoheterocyclic compound / Azacycle / Oxacycle / Hydrocarbon derivative / Organic oxide
show 9 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Tolaxatone [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin binding
Specific Function
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral...
Gene Name
MAOA
Uniprot ID
P21397
Uniprot Name
Amine oxidase [flavin-containing] A
Molecular Weight
59681.27 Da
References
  1. Tolaxatone [Link]

Drug created on October 23, 2015 16:16 / Updated on June 02, 2018 08:18